Tacrolimus ointment is effective for psoriasis on the face and intertriginous areas in pediatric patients.
Children with psoriasis often have involvement of the face and intertriginous areas. While corticosteroids have been the mainstay of treatment for plaque-type psoriasis, the face and intertriginous areas are more sensitive to local effects of topical steroid use such as cutaneous atrophy. Topical tacrolimus has shown promise in adult patients as an alternative antiinflammatory without the cutaneous side effects of steroids. Eleven patients between 6 and 15 years of age with facial or inverse psoriasis were evaluated in a 6-month, single-center, open-label trial. Clinical evaluations were made at baseline and days 30, 90, and 180. Severity was assessed using the physician's global assessment of improvement relative to baseline, a 6-point rating scale for signs of disease (erythema, infiltration, desquamation), and an overall severity score. Within the first 30 days of treatment, every patient had cleared or achieved excellent improvement with the use of tacrolimus ointment. Statistically significant improvement was achieved in each sign of disease and the overall severity score. The only adverse event reported in 6 months of observation was significant pruritus in one patient. We therefore conclude that tacrolimus ointment is an effective treatment for psoriasis on the face or intertriginous areas in children.
Brune
Adriana
A
Department of Dermatology, Northwestern University's Feinberg School of Medicine, 676 N. St. Clair Street, Chicago, IL 60611, USA.
Miller
Drew W
DW
Lin
Peggy
P
Cotrim-Russi
Daniela
D
Paller
Amy S
AS
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005148:Facial Dermatoses / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007402:Intertrigo / Q000188:drug therapy*; D008297:Male; D009824:Ointments; D010865:Pilot Projects; D011446:Prospective Studies; D011565:Psoriasis / Q000188:drug therapy*; D016559:Tacrolimus / Q000627:therapeutic use*; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D009824:Ointments; D016559:Tacrolimus